Vallon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own52.96% Shs Outstand9.14M Perf Week-44.18%
Market Cap5.20M Forward P/E- EPS next Y-0.99 Insider Trans0.00% Shs Float3.21M Perf Month-53.33%
Income-9.30M PEG- EPS next Q-0.23 Inst Own6.80% Short Float10.01% Perf Quarter-89.81%
Sales- P/S- EPS this Y-100.90% Inst Trans-3.12% Short Ratio0.09 Perf Half Y-88.14%
Book/sh1.28 P/B0.44 EPS next Y16.10% ROA- Target Price12.00 Perf Year-85.02%
Cash/sh0.56 P/C1.02 EPS next 5Y- ROE- 52W Range0.49 - 10.36 Perf YTD-90.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-94.50% Beta-
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low16.33% ATR0.21
Employees3 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)27.82 Volatility27.24% 19.33%
OptionableNo Debt/Eq0.03 EPS Q/Q- Profit Margin- Rel Volume0.04 Prev Close0.57
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.70M Price0.57
Recom2.00 SMA20-52.64% SMA50-75.70% SMA200-88.62% Volume29,748 Change0.11%
May-13-22 08:30AM  
May-12-22 08:30AM  
May-11-22 08:35AM  
May-09-22 04:05PM  
Apr-22-22 08:00AM  
Mar-23-22 08:00AM  
Mar-21-22 11:02AM  
Mar-04-22 02:34PM  
Feb-28-22 04:05PM  
Feb-14-22 04:15PM  
Jan-25-22 09:54AM  
Jan-20-22 08:35AM  
Jan-18-22 08:05AM  
Jan-12-22 10:35AM  
Jan-04-22 08:05AM  
Dec-23-21 08:05AM  
Dec-12-21 04:27AM  
Nov-12-21 08:05AM  
Nov-11-21 08:05AM  
Nov-10-21 08:35AM  
Nov-04-21 02:30PM  
Nov-01-21 08:35AM  
Oct-26-21 03:23PM  
Oct-12-21 08:35AM  
Sep-14-21 08:05AM  
Aug-11-21 08:05AM  
Aug-10-21 08:05AM  
Jul-13-21 08:05AM  
May-30-21 04:48AM  
May-19-21 08:15AM  
May-13-21 09:15AM  
May-11-21 09:05AM  
May-07-21 08:05AM  
Apr-26-21 09:05AM  
Apr-13-21 08:05AM  
Mar-29-21 08:05AM  
Mar-03-21 08:35AM  
Feb-23-21 09:05AM  
Feb-12-21 03:30PM  
Feb-09-21 10:24PM  
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Leanne M.Chief Financial OfficerJun 04Buy4.081,5086,1536,250Jun 04 04:06 PM
Kelly Leanne M.Chief Financial OfficerJun 03Buy4.051,0854,3944,742Jun 04 04:06 PM
Kelly Leanne M.Chief Financial OfficerJun 02Buy4.003,65714,6283,657Jun 04 04:06 PM